Development of new generation immunologically based cytokine storm inhibitors remains an important endeavor. Even if a successful vaccine is developed for COVID-19 patients, there will be ongoing mortality in vulnerable populations after vaccination as has been observed in flu virus and other current or future coronavirus infections as well as those with sepsis. In these conditions, resolution or chronicity of disease depends upon the strength of regulatory immune processes which appear to be compromised in COVID-19 patients that develop ARDS. To this end, the DRhQ construct could lend a helping hand.